In the News
This Scientist Turned CEO Wants to Gene-Edit a Way to Cure Cancer
In a fashionable fitted blazer, Rachel Haurwitz looks the part of a polished executive when she meets me in the largest conference room of her company, Caribou Biosciences. She’s sharp and tactical as she speaks, even though it was just a few years ago that Haurwitz traded her lab coat for a tailored suit and stepped up to lead a staff of 46 as Caribou’s CEO.
Diverse Perspectives — Insights for 2018 From Biopharma's Leading Women
When recruiting for last year’s executive outlook article, What 13 Life Science Trendsetters Expect For 2017 And Beyond, I made a concerted effort to have diversity well represented. And while we succeeded in getting a wide cross section of diverse opinions from very different organizations, I failed when it came to having female life science leaders well represented. This year Life Science Leader had 12 CEOs agree to participate (the highest number of CEOs to ever take part in this article), and five of these are women.
Meet the 30 biotech leaders under 40 who are searching for breakthrough treatments and shaping the future of medicine
Rachel Haurwitz, 32, wants to transform everything from livestock to medications using the revolutionary gene-editing technology CRISPR.
In the CRISPR pipeline – Rachel Haurwitz, CEO Caribou Biosciences
In June I met Rachel Haurwitz, CEO of Caribou Biosciences, at the Pioneers Festival in Vienna and we talked about the future of gene-editing and the CRISPR pipeline.
Caribou Biosciences is a biotechnology startup that develops cellular engineering and analysis solutions based on CRISPR-Cas technology. It was founded by members of the Doudna Laboratory at the University of California. Rachel is Caribou´s CEO. The Fortune Magazine named her to the “40 Under 40” list of the most influential young people in business.
MIT Technology Review: 35 Innovators Under 35
Meet the people who are taking innovations like CRISPR and flexible electronics and turning them into businesses.